Is AKTS or ALLO more undervalued in 2026?

CirclFi compares Aktis Oncology, Inc. (AKTS) and Allogene Therapeutics, Inc. (ALLO) using 13 institutional-grade valuation models. AKTS has a Quality of Company score of 1.6/10 while ALLO scores 4.7/10.

Which is a better buy — AKTS or ALLO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AKTS and ALLO valuations compare?

AKTS at $20.74 and ALLO at $2.17 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AKTS vs ALLO Valuation Comparison 2026 — Intrinsic Value Analysis

AKTS

Biotechnology

Aktis Oncology, Inc.

Quality

1.6

out of 10

Value Trap

—

Price

$20.74

Last close

Models

8/13

Active

ALLO

Biotechnology

Allogene Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$2.17

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	AKTS Fair Value	AKTS Upside	ALLO Fair Value	ALLO Upside
Bayesian DCF	Intrinsic	$5.49	-73.5%	$0.53	-75.4%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.68	-82.3%	$0.05	-97.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$10.07	-51.5%	$2.17	-0.1%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AKTS vs ALLO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AKTS vs ALLO — Which Stock Is More Undervalued?

ALLO scores higher with a 4.7/10 quality rating vs AKTS's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aktis Oncology, Inc. (AKTS) and Allogene Therapeutics, Inc. (ALLO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AKTS currently trades at $20.74 with a QOC of 1.6/10, while ALLO trades at $2.17 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).